A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

NCT01649024 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Malignant Mesothelioma

Interventions

DRUG: Tremelimumab

Sponsor

Azienda Ospedaliera Universitaria Senese